Enterococcus faecium Infections
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Pipeline Review, H2<br />
2015 Now Available at iData Insights<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Pipeline Review, H2 2015 Summary Global Markets Direct s,<br />
<strong>Enterococcus</strong> Faecium <strong>Infections</strong> - Pipeline Review, H2 2015 , provides an overview of the <strong>Enterococcus</strong><br />
Faecium <strong>Infections</strong> s therapeutic pipeline. This report provides comprehensive information on the<br />
therapeutic development for <strong>Enterococcus</strong> Faecium <strong>Infections</strong>, complete with comparative analysis at<br />
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type, along with latest updates, and featured news and press<br />
releases. It also reviews key players involved in the therapeutic development for <strong>Enterococcus</strong> Faecium<br />
<strong>Infections</strong> and special features on late-stage and discontinued projects. Global Markets Directs report<br />
features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000<br />
indications. The report is built using data and information sourced from Global Markets Directs<br />
proprietary databases, Company/University websites, SEC filings, investor presentations and featured<br />
press releases from company/university sites and industry-specific third party sources, put together by<br />
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation<br />
following a stringent set of processes that ensures that all the profiles are updated with the latest set of<br />
information. Additionally, processes including live news & deals tracking, browser based alert-box and<br />
clinical trials registries tracking ensure that the most recent developments are captured on a real time<br />
basis. The report enhances decision making capabilities and help to create effective counter strategies<br />
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to<br />
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed<br />
or altered based on the availability and relevance of data for the indicated disease. Scope - The report<br />
provides a snapshot of the global therapeutic landscape of <strong>Enterococcus</strong> Faecium <strong>Infections</strong> - The report<br />
reviews key pipeline products under drug profile section which includes, product description, MoA and<br />
R&D brief, licensing and collaboration details & other developmental activities - The report reviews key<br />
players involved in the therapeutics development for <strong>Enterococcus</strong> Faecium <strong>Infections</strong> and enlists all<br />
their major and minor projects - The report summarizes all the dormant and discontinued pipeline<br />
projects - A review of the <strong>Enterococcus</strong> Faecium <strong>Infections</strong> products under development by companies<br />
and universities/research institutes based on information derived from company and industry-specific<br />
sources - Pipeline products coverage based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages - A detailed assessment of monotherapy and<br />
combination therapy pipeline projects - Coverage of the <strong>Enterococcus</strong> Faecium <strong>Infections</strong> pipeline on<br />
the basis of target, MoA, route of administration and molecule type - Latest news and deals relating<br />
related to pipeline products Reasons to buy - Provides strategically significant competitor information,<br />
analysis, and insights to formulate effective R&D development strategies - Identify emerging players<br />
with potentially strong product portfolio and create effective counter-strategies to gain competitive<br />
advantage - Develop strategic initiatives by understanding the focus areas of leading companies -<br />
Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Enterococcus</strong> Faecium <strong>Infections</strong> - Plan mergers and acquisitions effectively by identifying key players of<br />
the most promising pipeline - Devise corrective measures for pipeline projects by understanding<br />
<strong>Enterococcus</strong> Faecium <strong>Infections</strong> pipeline depth and focus of Indication therapeutics - Develop and<br />
design in-licensing and out-licensing strategies by identifying prospective partners with the most<br />
1
attractive projects to enhance and expand business potential and scope - Modify the therapeutic<br />
portfolio by identifying discontinued projects and understanding the factors that drove them from<br />
pipeline.<br />
Browse with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=173355/enterococcus-<strong>faecium</strong>-infections-pipeline-review-h2-2015<br />
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173355/enterococcus-<strong>faecium</strong>-infections-pipeline-review-h2-2015<br />
Table of Contents<br />
Introduction 9<br />
Global Markets Direct Report Coverage 9<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> Overview 10<br />
Therapeutics Development 11<br />
Pipeline Products for <strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Overview 11<br />
Pipeline Products for <strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Comparative Analysis 12<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Therapeutics under Development by Companies 13<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Therapeutics under Investigation by Universities/Institutes 15<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Pipeline Products Glance 16<br />
Clinical Stage Products 16<br />
Early Stage Products 17<br />
Unknown Stage Products 18<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Products under Development by Companies 19<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Products under Investigation by Universities/Institutes 21<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Companies Involved in Therapeutics Development 22<br />
Alchemia Limited 22<br />
Alvogen Korea 23<br />
Aphios Corporation 24<br />
BioSource Pharm, Inc. 25<br />
Cellceutix Corporation 26<br />
2
ContraFect Corporation 27<br />
Helix BioMedix, Inc. 28<br />
Hsiri Therapeutics, LLC 29<br />
LegoChem Biosciences, Inc 30<br />
Lytix Biopharma AS 31<br />
Melinta Therapeutics, Inc 32<br />
MGB Biopharma Limited 33<br />
Microbiotix, Inc. 34<br />
MicuRx Pharmaceuticals, Inc. 35<br />
NovaBay Pharmaceuticals, Inc. 36<br />
Novan, Inc. 37<br />
NovoBiotic Pharmaceuticals, LLC 38<br />
Omnia Molecular Ltd. 39<br />
Oragenics, Inc. 40<br />
Sealife PHARMA GMBH 41<br />
Sentinella Pharmaceuticals, Inc. 42<br />
Sumitomo Dainippon Pharma Co., Ltd. 43<br />
TAXIS Pharmaceuticals, Inc. 44<br />
Wockhardt Limited 45<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Therapeutics Assessment 46<br />
Assessment by Monotherapy Products 46<br />
Assessment by Target 47<br />
Assessment by Mechanism of Action 49<br />
Assessment by Route of Administration 51<br />
Assessment by Molecule Type 53<br />
Drug Profiles 55<br />
auriclosene - Drug Profile 55<br />
3
Product Description 55<br />
Mechanism of Action 55<br />
R&D Progress 55<br />
brilacidin tetrahydrochloride - Drug Profile 57<br />
Product Description 57<br />
Mechanism of Action 57<br />
R&D Progress 57<br />
BSPC-728 - Drug Profile 59<br />
Product Description 59<br />
Mechanism of Action 59<br />
R&D Progress 59<br />
CF-304 - Drug Profile 60<br />
Product Description 60<br />
Mechanism of Action 60<br />
R&D Progress 60<br />
chrysophaentin - Drug Profile 61<br />
Product Description 61<br />
Mechanism of Action 61<br />
R&D Progress 61<br />
closthioamide - Drug Profile 62<br />
Product Description 62<br />
Mechanism of Action 62<br />
R&D Progress 62<br />
Epimerox - Drug Profile 63<br />
Product Description 63<br />
Mechanism of Action 63<br />
4
R&D Progress 63<br />
HB-1345 - Drug Profile 64<br />
Product Description 64<br />
Mechanism of Action 64<br />
R&D Progress 64<br />
HT-01 - Drug Profile 65<br />
Product Description 65<br />
Mechanism of Action 65<br />
R&D Progress 65<br />
HT-02 - Drug Profile 66<br />
Product Description 66<br />
Mechanism of Action 66<br />
R&D Progress 66<br />
IBN-1 - Drug Profile 67<br />
Product Description 67<br />
Mechanism of Action 67<br />
R&D Progress 67<br />
LCB-010371 - Drug Profile 69<br />
Product Description 69<br />
Mechanism of Action 69<br />
R&D Progress 69<br />
LCB-010699 - Drug Profile 71<br />
Product Description 71<br />
Mechanism of Action 71<br />
R&D Progress 71<br />
LTX-109 - Drug Profile 72<br />
Product Description 72<br />
5
Mechanism of Action 72<br />
R&D Progress 72<br />
Marinus - Drug Profile 74<br />
Product Description 74<br />
Mechanism of Action 74<br />
R&D Progress 74<br />
MBX-1162 - Drug Profile 75<br />
Product Description 75<br />
Mechanism of Action 75<br />
R&D Progress 75<br />
MGBBP-3 - Drug Profile 76<br />
Product Description 76<br />
Mechanism of Action 76<br />
R&D Progress 76<br />
MRX-I - Drug Profile 78<br />
Product Description 78<br />
Mechanism of Action 78<br />
R&D Progress 78<br />
MRX-IV - Drug Profile 79<br />
Product Description 79<br />
Mechanism of Action 79<br />
R&D Progress 79<br />
MU-1140 - Drug Profile 80<br />
Product Description 80<br />
Mechanism of Action 80<br />
R&D Progress 80<br />
6
NAI-107 - Drug Profile 82<br />
Product Description 82<br />
Mechanism of Action 82<br />
R&D Progress 82<br />
NAI-603 - Drug Profile 83<br />
Product Description 83<br />
Mechanism of Action 83<br />
R&D Progress 83<br />
NVN-1000 - Drug Profile 84<br />
Product Description 84<br />
Mechanism of Action 84<br />
R&D Progress 84<br />
OM-011818 - Drug Profile 85<br />
Product Description 85<br />
Mechanism of Action 85<br />
R&D Progress 85<br />
RX-05 - Drug Profile 86<br />
Product Description 86<br />
Mechanism of Action 86<br />
R&D Progress 86<br />
RXP-873 - Drug Profile 87<br />
Product Description 87<br />
Mechanism of Action 87<br />
R&D Progress 87<br />
SLP-0904 - Drug Profile 88<br />
Product Description 88<br />
Mechanism of Action 88<br />
7
R&D Progress 88<br />
SLP-0905 - Drug Profile 89<br />
Product Description 89<br />
Mechanism of Action 89<br />
R&D Progress 89<br />
SM-295291 - Drug Profile 90<br />
Product Description 90<br />
Mechanism of Action 90<br />
R&D Progress 90<br />
SM-369926 - Drug Profile 91<br />
Product Description 91<br />
Mechanism of Action 91<br />
R&D Progress 91<br />
Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 92<br />
Product Description 92<br />
Mechanism of Action 92<br />
R&D Progress 92<br />
Small Molecules for MRSA and Vancomycin-Resistant <strong>Enterococcus</strong> Faecium <strong>Infections</strong> - Drug Profile 93<br />
Product Description 93<br />
Mechanism of Action 93<br />
R&D Progress 93<br />
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE <strong>Infections</strong> - Drug Profile 94<br />
Product Description 94<br />
Mechanism of Action 94<br />
R&D Progress 94<br />
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial <strong>Infections</strong> - Drug Profile 95<br />
8
Product Description 95<br />
Mechanism of Action 95<br />
R&D Progress 95<br />
SP-2078 - Drug Profile 96<br />
Product Description 96<br />
Mechanism of Action 96<br />
R&D Progress 96<br />
Teixobactin - Drug Profile 98<br />
Product Description 98<br />
Mechanism of Action 98<br />
R&D Progress 98<br />
WCK-4086 - Drug Profile 100<br />
Product Description 100<br />
Mechanism of Action 100<br />
R&D Progress 100<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Recent Pipeline Updates 101<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Dormant Projects 119<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Discontinued Products 121<br />
<strong>Enterococcus</strong> <strong>faecium</strong> <strong>Infections</strong> - Product Development Milestones 122<br />
Featured News & Press Releases 122<br />
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 122<br />
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics<br />
Project 122<br />
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial<br />
Production of Lead Lantibiotic MU1140 123<br />
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-<br />
chlorotaurine And NVC-422 On Bacterial Toxins 123<br />
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 124<br />
9
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 124<br />
Appendix 125<br />
Methodology 125<br />
Coverage 125<br />
Secondary Research 125<br />
Primary Research 125<br />
Expert Panel Validation 125<br />
Contact Us 125<br />
Disclaimer 12"<br />
Read More http://www.idatainsights.com/reports-landing-page.php?id=173355/enterococcus<strong>faecium</strong>-infections-pipeline-review-h2-2015<br />
About Us:<br />
iData Insights which operates under Precision Research and Consulting Private Limited is a leading<br />
market research information aggregator and marketing research consulting firm. We conduct both<br />
primary and secondary research. Our work does not end with research it is also involved in distributing<br />
reports for different companies . We provide actionable recommendations and provide our expertise for<br />
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and<br />
discovery, and then be their guide in the implementation of changes that will make a difference to their<br />
bottom line.<br />
ContactUs:<br />
iData Insights<br />
Tel: 1-866-237-2965<br />
Web: http://www.idatainsights.com<br />
Email: info@idatainsights.com<br />
About iData Insights<br />
We work around the clock until our clients are completely satisfied with their promised results. It is our<br />
mission to provide timely services coupled with acute client care to create a long-lasting relationship<br />
with you. We deliver on our promise to provide results that are essential to the success of your<br />
company. We believe that by doing so, we will earn the trust of our clients for future projects<br />
10
11
Change language